Novo Nordisk Stock Plummets Amid Earnings Disappointment and Guidance Cut
Novo Nordisk shares tumbled 7.2% following a weaker-than-expected earnings report and downward revision of full-year sales and operating profit targets. The pharmaceutical giant's GLP-1 drugs, Wegovy and Ozempic, face mounting pressure from compounders offering tailor-made alternatives.
Wall Street analysts delivered downgrades, shifting ratings to "equal-weight" and "neutral" as skepticism grows over management's optimistic outlook. While near-term challenges persist, the long-term investment thesis remains intact for patient capital.